Drugs / lrinotecan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07594964 Background | Aug 2025 → Oct 2029 expected | biliary tract cancer, gastric cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma | Shenzhen Xinhe Biomedical | Recruiting | No outcome recorded |
| — | NCT07114666 Background | Aug 2025 → Aug 2029 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lrinotecan | “Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU” NCT07114666 ↗1“oxaliplatin+lrinotecan+calcium folinate+5-FU” NCT07594964 ↗ |